Emerging Company Profile
Apros: Engineering tissue-targeted TLR agonists
Emerging Company Profile: Apros is developing a pipeline of five TLR7 agonists targeting different tissues
Apros aims to increase the safety and tolerability of TLR agonists using a tissue-targeted approach, with lead candidate APR003 in Phase I to treat advanced colorectal cancer.
Apros is developing a suite of tissue-targeted TLR7 agonists for indications ranging from cancer to infectious disease that aim to avoid systemic toxicities that have plagued the drug class.
Lead candidate APR003, a TLR7 agonist designed to home